Each platform exists to solve a specific limitation of current metabolic therapy, and each is reused across programmes rather than built for a single asset.
A peptide and fusion-protein engineering toolkit for extending circulation time and controlling dosing interval — covering Fc- and albumin-based formats, unstructured polypeptides (XTEN, PAS) and other half-life-extension modules. Which module is chosen depends on the required dosing interval and the manufacturing route.
A peptide platform aimed at pancreatic β-cell regeneration, engineered for proteolytic stability and long dosing intervals. Chemistry, target and structural detail are disclosed under a confidentiality agreement. Platform science: friendly duration, with the epitope chemistry engineered for potency and manufacturability.
Design of single molecules carrying balanced activity across several metabolic receptors, so that glycaemic control, energy expenditure and weight can be addressed in one regimen. The receptor combination is disclosed under a confidentiality agreement.
Rational assembly of two therapeutic domains into one molecule, with linkers and terminus orientation determined by the structural requirements of each domain. Domain identity is disclosed under a confidentiality agreement. ntation chosen from the structural requirements of each domain.
Programmes advance through computational design and structure-based analysis, candidate selection, non-clinical pharmacology, CMC development and IND-enabling studies. Duration, mechanism pairing and manufacturability are treated as design inputs from the first round of optimisation.